Global Glaucoma Therapeutics Market Report and Forecast 2024-2032

Global Glaucoma Therapeutics Market Outlook

The global glaucoma therapeutics market value in 2023 was USD 6.94 billion driven by the increasing technological advancements in glaucoma diagnosis and treatment across the globe. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 to achieve a value of USD 10.96 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America to be Among the Significant Regional Markets for Glaucoma Therapeutics

North America is expected to be one of the leading regions in the glaucoma therapeutics market owing to high per capita expenditure on healthcare. Major players operating in the market have made a series of strategic acquisitions, contributing to their market share. Further, the increase in the geriatric population, rise in awareness about glaucoma, availability of reimbursements, and well-established health care infrastructure are the other factors driving the market growth in North America.
 

Europe and the Asia Pacific to Witness Significant Growth

The glaucoma therapeutics market in Europe is expected to increase due to favourable reimbursement policies during the forecast period. Factors contributing to the growth of the market in the region include stronger emphasis by federal governments on improving healthcare facilities and a rise in awareness among the population. On the other hand, the Asia Pacific would showcase the highest growth, fuelled by the increasing ageing population, especially in Japan and China, which require these therapeutics.
 

Market Segmentations

Various therapy options for primary open-angle (POA) and primary angle-closure (PAC) glaucoma are referred to as glaucoma therapeutics. The condition is marked by structural alterations in the optic nerves, resulting in vision loss and blindness. Topical eye drops, which include beta-blockers, prostaglandin analogues, cholinergic, carbonic anhydrase inhibitors, and alpha-adrenergic agonists, can treat glaucoma.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By drug class, the market includes:

• Prostaglandin Analogues
• Beta-Blockers
• Alpha Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Combination Drugs
• Others

Based on indication, the market is divided into:

• Open-Angle Glaucoma
• Angle Closure Glaucoma
• Others

The end-uses of the market are:

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgery Centres
• Others

The regional markets for the glaucoma therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Prevalence of Glaucoma Propelling the Market Growth

One of the major factors driving the market's growth is the rising prevalence of glaucoma across the globe. Glaucoma is quite common among diabetic patients and people with additional visual problems, such as age-related macular degeneration (AMD), cataracts, and dry eye. Following this, the growing geriatric population, which is more vulnerable to such illnesses, propels the market growth. An increase in awareness of glaucoma, medical coverage of glaucoma patients and demand for combination glaucoma drugs are some of the significant trends that can be seen in the global glaucoma therapeutics industry. The industry is also being driven by rising health consciousness among the public and a growing preference for laser glaucoma surgery.

In addition, the invention of unique combination dugs is a growth-stimulating factor. Anti-glaucoma medicines and prostaglandin analogues are being developed by pharmaceutical companies in combination with two or more drugs to lower excessive IOP levels. Other factors, such as the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure, are expected to fuel the market growth further.
 

Key Players in the Global Market for Glaucoma Therapeutics

The report gives a detailed analysis of the following key players in the global glaucoma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Aerie Pharmaceuticals Inc.
• Bausch & Lomb Incorporated 
• Inotek Pharmaceuticals Corp.
• SIFI S.p.A
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report